Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2214-2225

  Sorenson, Robert C ^a,b,e   Bisgaier, Charles L ^c,f   Aviram, Michael ^d   Hsu, Cary ^a   Billecke, Scott ^a   La Du, Bert N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Esperion Therapeutics Inc   (United States)

Author keywords

Atherogenesis; HDL; LDL oxidation; Lipid peroxidation; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME STABILITY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 0032877947     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2214     Document Type: Article

References (57)

1. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press; 1992:51-91.
2. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
3. Mackness MI, Arrol S, Abbott C Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
4. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
5. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
6. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617-1624.
7. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7:69-76.
8. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32:671-673.
9. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
10. Ruiz J. Diabetes mellitus and the late complications: influence of the genetic factors. Diabetes Metab. 1997;23(suppl 2):57-63.
11. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17:1067-1073.
12. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
13. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62:36-44.
14. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet. 1998;62:20-24.
15. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17:3565-3569.
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
17. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
18. Shin DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
19. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33:832-839.
20. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
21. Tanaka-Kawai H, Yomoda S. Molecular weight and substrate characteristics of human serum arylesterase following purification by immuno-affinity chromatography. Clin Chim Acta. 1993;215:127-138.
22. Kuo CL, La Du BN. Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos. 1995;23:935-944.
23. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19:100-106.
24. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
25. Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of rabbit and human serum paraoxonase. Biochemistry. 1991;30:10133-10140.
26. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991;30:10141-10149.
27. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A. 1995;92: 7187-7191.
28. Li WF, Matthews C, Disteche CM, Costa LG, Furlong CE. Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics. 1997;7:137-144.
29. Shin DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97: 1630-1639.
30. von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res. 1986;14:4683-4690.
31. von Heijne G. Signals for protein targeting into and across membranes. Subcell Biochem. 1994;22:1-19.
32. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Strahl K. Introduction of DNA Into Mammalian Cells. New York, NY: John Wiley & Sons; 1993. Ch 9.
33. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214-227.
34. Chen CH, Albers JJ. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin:cholesterol acyltransferase activity. J Lipid Res. 1982;23:680-691.
35. Blum CB, Dell RB, Palmer RH, Ramakrishnan R, Seplowitz AH, Goodman DS. Relationship of the parameters of body cholesterol metabolism with plasma levels of HDL cholesterol and the major HDL apoproteins. J Lipid Res. 1985;26:1079-1088.
36. Blum CB, Aron L, Sciacca R. Radioimmunoassay studies of human apolipoprotein E. J Clin Invest. 1980;66:1240-1250.
37. Williamson R, Lee D, Hagaman J, Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A. 1992;89:7134-7138.
38. Scanu AM, Edelstein C. Solubility in aqueous solutions of ethanol of the small molecular weight peptides of the serum very low density and high density lipoproteins: relevance to the recovery problem during delipidation of serum lipoproteins. Anal Biochem. 1971;44:576-588.
39. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 1983;24:886-898.
40. Bisgaier CL, Sachdev OP, Megna L, Glickman RM. Distribution of apolipoprotein A-IV in human plasma. J Lipid Res. 1985;26:11-25.
41. Kitchen BJ, Masters CJ, Winzor DJ. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem J. 1973;135:93-99.
42. Zech R, Rockseisen M, Kluge K, Dewald K, Armstrong VW, Chemnitius JM. Lipoproteins and hydrolysis of organophosphorus compounds. Chem Biol Interact. 1993;87:85-94.
43. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
44. Plump AS, Azrolan N, Odaka H, Wu L, Jiang X, Tall A, Eisenberg S, Breslow JL. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res. 1997;38:1033-1047.
45. Graham A, Hassall DG, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:193-204.
46. Mackness MI, Walker CH, Carlson LA. Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem. 1987;33:587-588.
47. Mackness MI, Peuchant E, Dumon MF, Walker CH, Clerc M. Absence of 'A'-esterase activity in the serum of a patient with Tangier disease. Clin Biochem. 1989;22:475-478.
48. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.
49. Weitman SD, Vodicnik MJ, Lech JJ. Influence of pregnancy on parathion toxicity and disposition. Toxicol Appl Pharmacol. 1983;71:215-224.
50. Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res. 1995;36:148-157.
51. Bonomo EA, Swaney JB. Effect of phosphatidylethanolamine on the properties of phospholipid-apolipoprotein complexes. Biochemistry. 1990;29:5094-5103.
52. Smith AB, Esko JD, Hajduk SL. Killing of trypanosomes by the human haptoglobin-related protein. Science. 1995;268:284-286.
53. Massamiri T, Tobias PS, Curtiss LK. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. J Lipid Res. 1997;38: 516-525.
54. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo SL, Sorenson RC, Standiford TJ. On the biological role(s) of paraoxonases. Chem Biol Interact. In press.
55. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040-12044.
56. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immuno-localization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-1238.
57. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 1997;416:377-380.